Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON PLC (ICLR) delivers essential clinical research services across 100+ countries, supporting pharmaceutical and biotechnology development through all trial phases. This news hub provides investors and industry professionals with timely updates on operational milestones, financial performance, and strategic initiatives shaping global drug development.
Access authoritative reporting on regulatory submissions, partnership announcements, and clinical trial advancements directly impacting ICON's market position. Our curated feed eliminates information fragmentation by centralizing earnings calls, governance updates, and technology implementations critical for evaluating contract research organizations.
Key coverage areas include phase III trial initiations, FDA/EMA regulatory interactions, acquisition strategies, and capacity expansion projects. Bookmark this page for real-time updates on ICON's patient recruitment innovations and quality control enhancements that maintain compliance with evolving global standards.
ICON plc (NASDAQ: ICLR) reported a strong Q2 2021, showcasing a record net business win of $1,106 million and a remarkable revenue increase of 40.5% year-over-year to $871 million. Adjusted EPS surged by 76.8% to $2.12. The acquisition of PRA is poised to enhance growth and shareholder value, with updated revenue guidance for 2021 between $5,300 million and $5,500 million. Cash generated from operations was $128.4 million, while net cash reached $707.2 million. Overall, the results highlight a robust financial position and positive outlook for the company.
ICON plc (NASDAQ: ICLR) successfully held its Annual General Meeting (AGM) on July 20, 2021, where all recommended resolutions were passed by shareholders. Key resolutions included re-election of directors, approval of financial reports, and authorizations for share allotment and market purchases. Approximately 45.4 million votes were cast. Notable outcomes were re-elections of Ciaran Murray, Joan Garahy, and Eugene McCague, alongside approvals for the fixing of auditors’ remuneration and disapplication of pre-emption rights. The company continues to emphasize growth and innovation in clinical research.
ICON plc (NASDAQ: ICLR) has completed its acquisition of PRA Health Sciences, forming a combined entity with 38,000 employees across 47 countries. The merger aims to create a leading healthcare intelligence and clinical research organization, enhancing clinical trials and accelerating drug development through advanced technology and diverse patient access. PRA shareholders received $80 in cash and 0.4125 shares of ICON stock. This strategic move positions ICON to improve biopharma customers' success in bringing essential medicines and devices to market.
ICON plc (NASDAQ: ICLR) announced the proposed acquisition of PRA Health Sciences, with the merger set to occur through ICON's wholly-owned subsidiary. The company plans to issue $500 million in Senior Secured Notes at 2.875% interest due 2026, replacing a previously planned offering of $1,515 million in 2028 notes due to an increase in credit facilities. The proceeds will fund the merger payment, refinance existing debt, and cover related expenses. The offering is expected to close on July 1, 2021, pending customary conditions.
ICON (NASDAQ: ICLR) announced the successful passing of all resolutions at its Extraordinary General Meeting held on June 15, 2021. Shareholders approved the issuance of ordinary shares related to the acquisition of PRA Health Sciences. The merger will see PRA operate as a subsidiary of ICON. Furthermore, PRA's stockholders also voted to adopt the Merger Agreement and approve executive compensation arrangements tied to the transaction. The merger is expected to close on July 1, 2021, pending any remaining conditions.
ICON plc (NASDAQ: ICLR) announced plans to acquire PRA Health Sciences via a merger, with a proposed offering of $2.015 billion in Senior Secured Notes. The funds will be used for cash consideration in the merger, refinancing existing debt, and covering related fees. The offering consists of $500 million of notes due 2026 and $1.515 billion due 2028, subject to market conditions. Successful completion of the merger depends on obtaining necessary approvals and satisfying closing conditions, which may present risks and uncertainties.
ICON plc (NASDAQ: ICLR), a leading global provider of outsourced drug and device development, announced key presentations at upcoming healthcare conferences. Mr. Brendan Brennan, CFO, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 08:00 AM ET. Dr. Steve Cutler, CEO, will present at the William Blair 41st Growth Stock Conference on June 2, 2021, at 11:40 AM ET. Live webcasts will be available on their Investor section. The company continues its strategic growth and service expansion in clinical development.
ICON plc (NASDAQ: ICLR), a leading global provider of outsourced drug and device development services, announced that CFO Brendan Brennan will present at two upcoming virtual healthcare conferences. The first presentation is scheduled for May 12, 2021, at the BofA Securities 2021 Virtual Healthcare Conference, followed by the UBS Virtual Global Healthcare Conference on May 24, 2021. For updates on these events, please check the Investor section of ICON's website. The company, headquartered in Dublin, employs approximately 16,070 staff across 89 locations globally.
ICON (NASDAQ: ICLR) reported strong financial results for Q1 2021 with revenue reaching $858 million, a 20% year-on-year increase. The company achieved record net business wins of $1.1 billion, up 27% year-on-year, and grew its backlog to $10 billion. Adjusted earnings per share rose 21% to $2.06. ICON has raised its full-year revenue guidance to $3.4 - $3.5 billion, reflecting a 21.6% - 25.1% increase year-on-year. The planned acquisition of PRA is set to close in July, enhancing ICON's market position.
ICON plc (NASDAQ: ICLR) recently announced that CFO Brendan Brennan will present at two significant events: the Barclays Global Healthcare Conference on March 10, 2021, at 08:00 am ET, and at the KeyBanc Capital Markets' Life Sciences & MedTech Investor Forum on March 24, 2021, at 11:30 am ET. The presentations will be accessible via live webcasts, with details available on the Investor section of ICON's website under 'Events.' ICON is a leading provider of outsourced drug and device development services, currently employing approximately 15,730 staff globally.
